

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 1, 2024**

---

**GlycoMimetics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-36177**  
(Commission File Number)

**06-1686563**  
(IRS Employer  
Identification No.)

**9708 Medical Center Drive  
Rockville, MD 20850**  
(Address of principal executive offices, including zip code)

**(240) 243-1201**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.001 par value	GLYC	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.03****Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

At the 2024 Annual Meeting of Stockholders held on May 1, 2024 (the “*Annual Meeting*”), the stockholders of GlycoMimetics, Inc. (the “*Company*”) approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “*Restated Certificate*”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 to 150,000,000 shares and (ii) an amendment to the Restated Certificate to include a provision eliminating or limiting monetary liability for specified corporate officers for breach of fiduciary duty in certain actions as permitted by the General Corporation Law of the State of Delaware. The increase in the authorized number of shares of the Company’s common stock and the addition of the officer exculpation provision were effected pursuant to Certificates of Amendment of the Amended and Restated Certificate of Incorporation (the “*Certificates of Amendment*”) filed with the Secretary of State of the State of Delaware on May 1, 2024 and were effective as of such date.

The foregoing description is qualified in its entirety by the Certificates of Amendment, which are attached as Exhibits 3.1 and 3.2 to this Current Report on Form 8-K and are incorporated herein by reference.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

At the Annual Meeting held on May 1, 2024, the stockholders of the Company considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 1, 2024 (the “*Proxy Statement*”). Of the 64,450,385 shares outstanding as of the record date, 50,481,107 shares, or 78.3%, were present or represented by proxy at the Annual Meeting.

The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

**Proposal No. 1:** Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

Name	Votes For	Votes Withheld
Daniel Junius	34,583,868	2,665,886
Rachel King	37,007,330	242,424

Broker Non-Votes: 13,231,353

**Proposal No. 2:** Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows:

	Votes For	Votes Against	Abstentions
Ratification of appointment of Ernst & Young LLP	50,319,444	40,448	121,215

**Proposal No. 3:** Stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The votes were cast as follows:

	Votes For	Votes Against	Abstentions
Approval, on an advisory basis, of the executive compensation of the named executive officers.	35,292,808	1,881,276	75,670

Broker Non-Votes: 13,231,353

**Proposal No. 4:** Stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “*Restated Certificate*”) to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares. The votes were cast as follows:

	<u>Votes For</u>	<u>Votes Against</u>	<u>Abstentions</u>
Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000.	49,332,242	1,014,592	134,273

Broker Non-Votes: 0

**Proposal No. 5:** Stockholders approved an amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation. The votes were cast as follows:

	<u>Votes For</u>	<u>Votes Against</u>	<u>Abstentions</u>
Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.	36,172,684	1,045,748	31,322

Broker Non-Votes: 13,231,353

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<u>Exhibit Number</u>	<u>Exhibit Description</u>
3.1	<a href="#">Certificate of Amendment of the Amended and Restated Certificate of Incorporation.</a>
3.2	<a href="#">Certificate of Amendment of the Amended and Restated Certificate of Incorporation.</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLYCOMIMETICS, INC.**

Date: May 2, 2024

By: /s/ Brian M. Hahn  
Brian M. Hahn  
Senior Vice President and Chief Financial Officer

**CERTIFICATE OF AMENDMENT  
TO THE CERTIFICATE OF INCORPORATION OF  
GLYCOMIMETICS, INC.**

**GlycoMimetics, Inc.**, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “*Company*”), hereby certifies that:

**FIRST:** The name of this Company is GlycoMimetics, Inc.

**SECOND:** The Company’s original Certificate of Incorporation was filed on April 4, 2003. The Certificate of Incorporation was last amended and restated on January 15, 2014.

**THIRD:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending Paragraph A of Article IV of the Amended and Restated Certificate of Incorporation to read in its entirety:

“The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares of all classes of capital stock which the Company shall have authority to issue is One Hundred Fifty-Five Million (155,000,000) shares, of which One Hundred Fifty Million (150,000,000) shares shall be Common Stock (the “*Common Stock*”), each having a par value of one-tenth of one cent (\$0.001), and Five Million (5,000,000) shares shall be Preferred Stock (the “*Preferred Stock*”), each having a par value of one-tenth of one cent (\$0.001).”

**FOURTH:** This Certificate of Amendment to the Amended and Restated Certificate of Incorporation was submitted to the stockholders of the Company and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporate Law of the State of Delaware.

\* \* \* \* \*

**IN WITNESS WHEREOF**, the Company has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this 1<sup>st</sup> day of May, 2024.

**GLYCOMIMETICS,  
INC.**

By: /s/ Harout Semerjian  
Harout Semerjian  
President and Chief  
Executive Officer

---

**CERTIFICATE OF AMENDMENT  
TO THE CERTIFICATE OF INCORPORATION OF  
GLYCOMIMETICS, INC.**

**GlycoMimetics, Inc.**, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “*Company*”), hereby certifies that:

**FIRST:** The name of this Company is GlycoMimetics, Inc.

**SECOND:** The Company’s original Certificate of Incorporation was filed on April 4, 2003. The Certificate of Incorporation was last amended and restated on January 15, 2014.

**THIRD:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending the Amended and Restated Certificate of Incorporation to add new Article IX, which shall read in its entirety:

**“IX.**

Limitation of Liability for Officers. An Officer (as defined below) of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of his or her fiduciary duty as an officer of the Company, except for liability (a) for any breach of the Officer’s duty of loyalty to the Company or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) for any transaction from which the Officer derived an improper personal benefit, or (d) arising from any claim brought by or in the right of the Company. If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Officers, then the liability of an Officer of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. For purposes of this Article IX, “Officer” shall mean an individual who has been duly appointed as an officer of the Company and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service by the delivery of process to the registered agent of the Company as contemplated by 10 Del. C. § 3114(b).

Any amendment, repeal or modification of this Article IX by either of (i) the stockholders of the Company or (ii) an amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director at the time of such amendment, repeal or modification.”

**FOURTH:** This Certificate of Amendment to the Certificate of Incorporation was submitted to the stockholders of the Company and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporate Law of the State of Delaware.

\* \* \* \* \*

**IN WITNESS WHEREOF**, the Company has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this 1<sup>st</sup> day of May, 2024.

**GLYCOMIMETICS,  
INC.**

By:       /s/       Harout  
              Semerjian  
              \_\_\_\_\_  
              Harout Semerjian  
              President and Chief  
              Executive Officer